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Abstract
Infectious disease nucleic acid amplification technologies (NAAT) have superior sensitivity,
specificity, and rapid time to result compared to traditional microbiological methods. Recov-
ery of concentrated, high quality pathogen nucleic acid (NA) from complex specimen matri-
ces is required for optimal performance of several NA amplification/detection technologies
such as polymerase chain reaction (PCR). Fully integrated NAAT platforms that enable
rapid sample-to-result workflows with minimal user input are generally restricted to larger
reference lab settings, and their complexity and cost are prohibitive to widespread imple-
mentation in resource limited settings (RLS). Identification of component technologies for
incorporation of reliable and affordable sample preparation with pathogen NA amplification/
detection into an integrated platform suitable for RLS, is a necessary first step toward
achieving the overarching goal of reducing infectious disease-associated morbidity and
mortality globally. In the current study, we evaluate the performance of six novel NA extrac-
tion technologies from different developers using blinded panels of stool, sputum and blood
spiked with variable amounts of quality-controlled DNA- and/or RNA-based microbes. The
extraction efficiencies were semi-quantitatively assessed using validated real-time reverse
transcription (RT)-PCR assays specific for each microbe and comparing target-specific RT-
PCR results to those obtained with reference NA extraction methods. The technologies
were ranked based on overall diagnostic accuracy (analytical sensitivity and specificity).
Sample input and output volumes, total processing time, user-required manual steps and
cost estimates were also examined for suitability in RLS. Together with the performance
analysis, these metrics were used to select the more suitable candidate technologies for fur-
ther optimization of integrated NA amplification and detection technologies for RLS.
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Introduction
An accurate and rapid diagnostic test can facilitate better patient care by informing prompt
and appropriate treatment, leading to decreased morbidity and mortality while saving money
and preventing improper use of antimicrobial drugs [1]. Rapid diagnostics are also critical to
identify pathogens for which targeted public health interventions can be employed to control
disease transmission in the community. Nucleic acid amplification technologies (NAAT) to
identify common pathogens have become a routine approach for infectious disease diagnosis
in high-income countries. Many NAAT products now exist that have been cleared or approved
by national health authority agencies, in addition to a variety of qualified laboratory-developed
methods used in some facilities [2,3]. Although various amplification methodologies have
been developed, RT-PCR is the predominant NAAT used for diagnostic testing [4]. The imple-
mentation of NAAT in clinical diagnostic laboratories is complex and can require sophisti-
cated equipment, infrastructure, skilled laboratorians, and a robust quality management
program [5]. These requirements present insurmountable challenges when trying to diagnose
infectious diseases in the resource limited settings (RLS) of low and middle-income countries
(LMIC), especially in rural environments where operational and logistical limitations further
challenge implementation [4,6]. Patients with communicable diseases in these locations would
greatly benefit from rapid on-site diagnosis and timely linkage to care, resulting in improved
individual outcomes and better infectious disease control.
The multifaceted challenges facing NAAT point-of-care testing in LMICs demand solutions
that can reliably integrate the often challenging nucleic acid (NA) extraction procedure,
together with a suitable NA amplification/detection method. This unified system must be sim-
ple to operate, environmentally robust, yield timely results, be affordable and have high diag-
nostic accuracy. NAAT-based diagnostic platforms that are developed for use in high-income
countries typically cannot tolerate the environmental extremes (e.g. temperature, humidity
and dust) encountered in RLS and are not designed for use by healthcare workers that have
not received extensive training [7,8]. These factors make most currently available sample-to-
answer NAAT options unsuitable for implementation in peripheral facilities in LMICs [5,9]. A
rapid time to result is necessary to reduce loss to follow up wherein the client may have multi-
ple constraints that prevent returning for test results and possible treatment; these include dis-
tances required for travel to the test site, time-off from work for the visit, limited financial
resources and other competing needs [10,11]. Currently, most NAAT test results for infectious
diseases are not available on the same day [12–14]. Cost per test is a further barrier to adop-
tion, as many LMICs cannot purchase these high-cost diagnostic tests without global donor
support [15]. For example, the WHO published a target product profile for a simple and accu-
rate diagnostic NAAT for Mycobacterium tuberculosis (MTB) to supplant smear microscopy
with a targeted price of US $4–6 [16]. For such settings, there is a global need for innovators to
design and develop low cost, fully integrated testing systems that meet required performance
criteria, while being functional in austere environments and applicable for a variety of patho-
genic agents.
As high quality NA extraction is a necessary first step toward an integrated platform, we
assessed the performance of six NA extraction technologies to efficiently extract high quality
NA from complex clinical sample matrices, such as sputum, stool and whole blood. A variety
of metrics were used to evaluate and assess the performance of these six platforms, with the
intent to determine if any might subsequently be integrated together with low-cost NA detec-
tion technologies, also suitable for RLS [4]. Blinded panels of quality controlled contrived spec-
imens of sputum, blood, and stool, spiked with varying levels of bacterial and/or viral agents
were used in a head-to-head challenge of these six NA extraction technologies. The
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performance of each was then compared using pathogen-specific real-time PCR assays for
each target. Other factors important for RLS were assessed, including specimen input volume
(largely for sensitivity), degree of automation, and processing time. Collectively, these data
were compiled and analyzed to gauge the suitability of these six technologies for future inclu-
sion into an LMIC-appropriate integrated testing system–a subject of ongoing interest to a
funder, the Bill and Melinda Gates Foundation (BMGF).
Materials and methods
Identification of technology developers
An extensive search of peer-reviewed literature, published technical reports and white papers,
commercial literature, company websites, conference proceedings, and letters of interest to a
donor (BMGF) was conducted to identify multiple technology developers with innovative NA
extraction methods with the potential for use in austere settings. Six developers agreed to par-
ticipate in this study based upon their estimated potential to meet a critical cost goal of approx-
imately $2 per extraction. The institutions included Akonni Biosystems, Inc. (Frederick, MD,
USA), Claremont BioSolutions (Upland, CA, USA), Integrated Nano-technologies (Henrietta,
NY, USA), MolBio Diagnostics (Bangalore, India), Paratus Diagnostics, (San Marcos, TX,
USA) and the Hasleton group, Vanderbilt University (Nashville, TN, USA). Although these
institutions had no role in designing the study, the authors agreed with the request that for
purposes of anonymity, the identities of each developer and associated technologies would be
coded for this report. These developers offered several innovative devices and NA extraction
methods incorporating various chemical, heat, and/or mechanical lysis, with solid phase NA
capture on silica or other NA-specific binding matrices coated onto beads, frits or other sup-
ports. The operating platforms ranged from prototype systems in development to further sim-
plify workflow, to fully integrated devices. Each developer received identical blinded specimen
panels to process in their facility. The isolated NAs were shipped to the Centers for Disease
Control and Prevention (CDC) for subsequent molecular analysis.
Specimen matrices
Multiple studies on the performance of NA platforms have been described previously thus this
work utilized real time PCR analyses of sample extracts to establish if sufficient amounts and
purity of target NAs were generated to give a positive result [17–19]. Human raw sputum,
whole blood and stool specimen matrices were used in this study because they are common
specimen types used for the diagnosis of many infectious diseases and because each is consid-
ered complex because of physiochemical attributes including viscosity, heterogeneity, extrane-
ous NAs, commensal microflora, cellular debris and the presence of PCR inhibitors [20–26].
As the intent of this study was to directly compare different NA extraction methods, the use of
contrived samples was deliberately chosen to limit the heterogeneity of each sample type as
compared to clinically derived samples. In addition, the acquisition of sufficient amounts of
excess or discarded clinical samples for use with multiple methods would have been extremely
challenging. Other groups have described use of contrived samples in order to compare the
performance of different extraction methods, test platforms and diagnostic laboratories host-
ing test platforms [19,27]. Aliquots of pooled raw human sputum (10 X 25 mL volumes) and
stool (3 X 75 g) were procured from BioIVT (Westbury, NY, USA). Bloodworks Northwest
(Seattle, WA, USA) provided one unit (~ 400 mLs) of human whole blood. Total NAs were
first extracted from these specimens and screened via real-time RT-PCR at PATH using the
protocols described below to confirm the absence of the target microbes included in in the pri-
mary specimens. The King County Tuberculosis Laboratory (Seattle, WA, USA) screened
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aliquots from the pooled sputum samples for the presence or absence of MTB via mycobacte-
rial growth indicator tubes (MGIT, Becton Dickinson, Franklin Lakes, NJ, USA) and Lo¨wen-
stein–Jensen and Middlebrook 7H10 agar slants.
Culture and preparation of microbial agents for specimen spiking
Each specimen type (stool, sputum, or whole blood) was spiked with bacteria and/or an RNA-
based virus to enable semi-quantitative PCR assessment of both DNA and RNA extraction effi-
ciencies from each specimen panel. All of the real time PCR assays used in this study are quali-
tative and not quantitative. To assess extraction performance, the specimen matrices were
spiked with target microbes at levels that represented high, medium and low levels of target. It
was assumed that all methods assessed in this exercise would detect the high levels and likely
the medium range with the detection of low levels from extracts being the primary indicator of
performance in terms of recovery and purity of the extract. MTB H37Rv strain Johannesburg
and a clinical isolate of influenza A (H3N1) were used for sputum spiking; Salmonella enterica
serovar Typhimurium LT2 and male specific 2 (MS2) bacteriophage were used for stool; and
Streptococcus pneumoniae and MS2 phage were used for whole blood. The inactivated MTB
cells were procured from the laboratory of Dr. Bavesh Kana (University of Witwatersrand,
Johannesburg, South Africa) and supplied in ten mLs of phosphate buffered saline (PBS) [28].
The MTB cells were originally cultured in Middlebrook 7H9 broth supplemented with 5%
glycerol with incubation at 37˚C. The MTB cells were chemically inactivated to ensure mini-
mal risk from laboratory-acquired infection during processing. No growth in MGIT after 42
days incubation confirmed the inactivation of MTB. The influenza A strain was an H3N1 clini-
cal isolate provided by the Washington State Department of Health Public Health laboratories
(Shoreline, WA, USA). Dr. Scott Meschke (University of Washington, Seattle, WA, USA)
gifted both MS2 phage and S. Typhimurium LT2. MS2 phage was propagated in an Escherichia
coli Famp+ strain as previously described [29], harvested from the soft agar overlay, filtered
through a 0.22 μm filter (EMD Millipore, Billerica, MA, USA), and stocks stored at 4˚C until
use. S. Typhimurium LT2 was cultured in tryptic soy broth (Sigma-Aldrich, St Louis, MI,
USA) with overnight incubation at 37˚C and shaking. The cells were pelleted by centrifuga-
tion, washed once with PBS, resuspended in 20 mLs PBS, and stored at 4˚C until use. S. pneu-
moniae (American Type Culture Collection, Manassas, VA, USA) was cultured at 37˚C
overnight in brain-heart infusion broth (Sigma-Aldrich). The cells were pelleted by centrifuga-
tion, washed once with PBS and resuspended in RPMI-1640/15% glycerol (Sigma-Aldrich) to
prevent autolysis [30]. The cell suspension was aliquoted in 1mL stock volumes and stored at
−80˚C until use.
Reference nucleic acid extraction methods for panel construction
With the exception of MTB, the extraction of the bacterial and viral NAs at the PATH labora-
tory was performed using Qiagen NA extraction kits (Hilden, Germany) as described below.
All NA eluates derived from extractions were stored at -80˚C until use.
Viral RNA from spiked sputum and blood panel members was extracted using 140 μL ali-
quots of each specimen, processed with the QIAamp viral RNA mini kit following the manu-
facturer’s protocol. All RNAs were eluted in a final volume of 60 μL. For viral RNA from
spiked stool panel members, a pre-RNA extraction clean-up step was done as follows. Briefly,
200 mg amounts of stool were homogenized in 800 μL PBS via vortexing and then clarified by
centrifugation for 20 minutes at 4,000 X g. The supernatant was filtered using a 0.22 μm filter
(EMD Millipore), and 140 μL aliquots of filtrate were then processed with the QIAamp viral
RNA mini kit. Bacterial DNA from blood was extracted using 200 μL processed with the
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QIAamp DNA blood mini kit and eluted in a final volume of 200 μL. Bacterial DNA from
stool was extracted from 200 mg using the QIAamp DNA Stool mini kit and eluted in 200 μL
volumes. MTB DNA was extracted from sputum using a previous methodology [31]. Briefly,
500 μL sample volumes were liquefied using an equal volume of 2% N-acetyl-L-cysteine and
incubated at room temperature for 15 minutes. PBS was added to a final volume of 50 mLs,
the cells pelleted by centrifugation, resuspended in 100 μL Tris EDTA buffer (pH8.0) contain-
ing acid-washed glass beads and disrupted for 2 min (Cell Disruptor Genie, Scientific Indus-
tries, Bohemia, NY, USA). The cell lysates were centrifuged and clarified supernatants
transferred to sterile microtubes.
Spiked target levels (described below) for the microbes in each panel were independently
confirmed at the CDC laboratory as follows. Briefly, all spiked samples were extracted using the
MagNA Pure Compact instrument with the Total Nucleic Acid Isolation Kit I external lysis pro-
tocol (Roche Applied Science, Indianapolis, IN, USA) and eluted in a final volume of 100 μL for
all extracts. Prior to NA extraction, the different specimen types were processed via alternative
methods. For sputum, 300 μL of each sample was first incubated with 300 μL dithiothreitol solu-
tion (ThermoFisher Scientific, Waltham, MA, USA) at room temperature for 1 hour prior to
extraction. For blood samples, 400 μL of blood was first mixed with 400 μL bacterial lysis buffer
(Roche), 400 μL pH neutral buffer, and 40 μL proteinase K (25 mg/mL) with subsequent incuba-
tion at ambient temperature for 15 minutes. Glass beads (800 mg, 0.5 mm) were added and the
cells were disrupted twice for one minute at 5000 rpm. The solution was then centrifuged at 10
000 × g for one minute and 700 μL of the supernatant used for extraction. For stool, 200 mg
were mixed with 2 mL PBS and then briefly centrifuged to pellet particulates. Four hundred μL
of the supernatant was combined with 400 μL bacterial lysis buffer (Roche), 400 μL pH neutral
buffer, and 40 μL proteinase K (25 mg/mL) and incubated at ambient temperature for 15 min-
utes. Glass beads (800 mg, 0.5mm) were added and cells disrupted twice for one minute at 5000
rpm. The solution was centrifuged at 10 000 × g for one minute, and 700 μL of supernatant was
used for extraction. All NA eluates were stored at -80˚C until use.
Reference methods for RT-PCR detection of nucleic acid targets for panel
construction
The PATH and the CDC laboratories both used the CDC-validated real-time RT-PCR assays
specific for each target microbe in this study. Oligonucleotide primers and probes were pro-
cured from IDT (Coralville, IA, USA). Real time PCR has previously been described as an
effective method by which to assess the performance of extraction methods in that it is highly
specific, it can detect very low levels of target and can indirectly inform on the purity of
extracted samples [17–19]. The core amplification reagent used in all real time RT-PCR assays
was qScript XLT 1-Step RT-qPCR ToughMix (Quanta Bio, Gaithersburg, MD, USA). All reac-
tions were conducted in 20 μL volumes into which 5 μL of NA extract was added to create a
final reaction volume of 25 μL. All reactions were processed under the same thermal cycling
protocol, irrespective of the RT-PCR instrument used or the target microbe and the specimen
matrix, and included use of a reverse transcription step. Cycling conditions were as follows:
45˚C for 10 min, 95˚C for 10 min, 45 cycles of 95˚C for 30 sec and 60˚C for 1 min. Fluores-
cence in the FAM channel was measured in real time during the 60˚C stage. Real-time
RT-PCR was performed on an Agilent Mx3005P qPCR system (Agilent Technologies, Santa
Clara, CA, USA) at the PATH laboratory and the Applied Biosystems 7500 Fast system (Ther-
moFisher Scientific, Waltham, MA) at the CDC laboratory.
Construction of DNA- and RNA-spiked blinded panels. Each pooled specimen panel
was comprised of ten sample members, with most spiked with a bacterial pathogen and/or an
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RNA-based virus to assess NA extraction efficiencies from the three specimen matrices
(Table 1). Each panel was comprised of seven spiked (positive) and three unspiked (negative)
samples. These were labelled SP1–10 (SPutum), BL1–10 (BLood), and ST1–10 (STool). Spu-
tum was spiked with MTB and/or influenza A virus; whole blood was spiked with S. pneumo-
niae and/or MS2 bacteriophage; and stool was spiked with S. Typhimurium LT2 and/or MS2
phage. The input amount of each test microbe used for spiking was semi-quantitatively deter-
mined via PCR Crossing threshold (Ct) values derived from the NA extracts of the various
agents. The intent was to spike samples with sufficient NA to represent high (Ct 18 ± 1.5),
medium (Ct 26 ± 1.5) and low (Ct 35 ± 1.5) amounts of test microbe NA in each specimen
panel, with corresponding levels of one microbe and/or the other [19].
The sputum (SP) panel was prepared by pooling 210 mLs of raw human sputum and blend-
ing to create a homogenous mixture. The homogenate was then split into ten 20 mL aliquots.
Eight aliquots were spiked with MTB cells and/or influenza A virions, again corresponding to
high, medium, and low Ct levels, and subsequently mixed to create a uniform distribution of
MTB cells and influenza A virions in the respective test panel samples. The SP panel samples
were dispensed into 0.5 mL aliquots for later use.
Whole blood (BL) was split into ten 36 mL aliquots. Eight aliquots were spiked with varying
concentrations of S. pneumoniae and MS2 phage corresponding to high, medium, or low Ct
levels. The spiked blood panels were then mixed to ensure an even distribution of spiking
agents. The ten BL panels were then aliquoted in 1 mL volumes.
For the construction of the stool (ST) panel, a 40% (w/v) stool homogenate in PBS was pre-
pared in a blender and aliquoted into ten 40 mL volumes. Eight samples were spiked with S.
Typhimurium and/or MS2 stocks corresponding to high, medium, or low Ct levels and distrib-
uted into 1 mL aliquots. After each sample set was prepared, the tubes were frozen using a dry
ice/ethanol bath and then stored at -80˚C until shipping or further use.
To ensure the Ct value from each spiked sample was within the expected range, the DNA
and RNA were extracted from representative aliquots in each panel following their construc-
tion. The NA extracts were then analyzed by real time RT-PCR assays specific to each spiked
microbe. Low-spiked samples representing each target microbe were also processed after a
freeze and thaw cycle to ensure sample integrity. NA extracts from the three specimen panels
were then independently tested by RT-PCR at the CDC to confirm the original test data
derived at the PATH laboratory. While the Ct values were typically in close agreement to the
PATH NA extracts, trace amounts of MTB DNA were consistently detected in Sample SP6, a
Table 1. Target-spike levels used in the construction of each specimen panel. The format of each panel was the
same. Samples were spiked with different microbes to represent varying levels of DNA and RNA for subsequent NA
extraction: +++ high spike (Ct 18 ± 1.5); ++ medium spike (Ct 26 ± 1.5); + low spike (Ct 35 ± 1.5);–no spike.
Sample RNA-based microbe DNA-based microbe
1 + +++
2 - -
3 - +++
4 +++ -
5 - +
6 - -
7 +++ +
8 - -
9 - ++
10 ++ -
https://doi.org/10.1371/journal.pone.0215753.t001
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supposedly MTB negative sample. This sample was removed from the sputum panel and there-
fore the final SP panel was comprised of only nine samples, each of which were present in trip-
licate aliquots. The 10 panel members for the remaining blood and stool panels were each
presented in triplicate.
The 87 test aliquots (less the three replicates of SP6) across the three specimen panels were
blinded via four-digit numbers and shipped overnight on dry ice to the developers with confir-
mation of the integrity of cold chain upon receipt. Each developer was asked to document the
amount of each sample used for each NA extraction, the final elution volume, the time
required and the number of user steps for extraction each panel. All NA extracts from each
developer were frozen and then shipped to the CDC laboratory on dry ice via overnight cou-
rier. The extracts were stored at -80˚C until testing. Ultimately, each blinded NA extract was
tested in triplicate via the CDC real time RT-PCR protocols for the corresponding microbial
NAs (three PCR reactions for each triplicate aliquot per panel member), and the Ct values
shared with the PATH laboratory for subsequent analyses.
The use of polar plots to rank technologies on multiple key attributes. The WHO cre-
ated the acronym ASSURED to list the key attributes necessary for an effective point of care
test, e.g. a rapid diagnostic test [32]. We can apply many of these attributes to the NA extrac-
tion technologies screened in this study except for E (Equipment-free) and D (Deliverable)
since all of the technologies require a device and none of these technologies are currently man-
ufactured or marketed at scale. In terms of A (Affordable), all of the developers consider their
technology costs $2 per test and so all were scored at this price. The SS (Sensitive and Specific)
data points are addressed with the analytical performance data described in the results section.
To address U (User-friendly) and R (Rapid), we applied the number of steps required to per-
form each extraction and the turnaround times for each method, respectively. Three polar
plots, one for each specimen panel, were generated for each developer based on the two target
NAs within each panel. All of the ASSUR components were individually normalized in a range
from low (0.0) to high (1.0) scores for each metric with 1.0 being the most optimal value mea-
sured in each category. The five normalized parameters of ASSUR calculated each plot were
equally weighted and the average of these parameters were calculated for each target microbe.
These averages were then pooled and re-averaged based on the sample type and also for all
three sample types and these values used to rank developers in terms of ASSUR.
Results
Real time RT-PCR qualification of microbe-spiked challenge panels
The real time RT-PCR Ct values from the original microbe-spiked challenge panels tested by
PATH (predominantly by Qiagen kits) were used as the reference standard to compare the
various NA extracts from sputum, blood and stool (see PATH columns, Table 2). The CDC
further qualified the three panels by ensuring that each specimen yielded similar results to the
PATH analyses after freezing, shipping, nucleic acid extraction via a different platform, the
Roche MagNaPure and analysis by real-time RT-PCR analysis (see CDC columns, Table 2).
The data from the SP and BL panels extracted by the MagNaPure (CDC) closely correlated
with the Qiagen (PATH) data with a +/- 2 variance observed between the mean Ct values
(Table 2). However, the stool panel data showed greater variance. Although the MS2 Ct values
were similar between the CDC and PATH results (Table 2), less S. Typhimurium DNA was
detected in the CDC NA extracts from the mid- and high-spiked ST panel members, with no
amplification detected in the low-spiked samples. This may be due to PATH using two sepa-
rate Qiagen kits to extract DNA and RNA respectively, from stool in order to optimize NA
recoveries. The CDC laboratory performed a single total NA extraction method with the
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MagNaPure that incorporated a brief centrifugation of liquefied stool samples to reduce debris
prior to extraction. This centrifugation step may explain the differences seen in S. Typhimur-
ium DNA levels, as many of the bacterial cells would likely have been removed in this step.
With the exception of S. Typhimurium, the CDC results verified the target NAs levels in all
panels (Table 1) and indicated that both the Qiagen and MagNaPure methods used in either
laboratory gave typically similar RT-PCR results. All annotated and complete real time
RT-PCR data sets from each group is available online (https://dataverse.harvard.edu/
dataverse/SSB).
Analytical sensitivity and specificity of the developer NA extracts from the
challenge panels
All developers completed the NA extractions using their respective technologies and shipped
the extracts to the CDC. Two minor deviations were observed: Developer E shipped only two
of the three ST3 and ST6 samples provided to them; and one extract of sample SP3 from devel-
oper C contained insufficient elution volume only allowing for influenza A screening and not
MTB.
With the above exceptions, NA extracts derived from all triplicate panel members were
tested in triplicate by real-time RT-PCR, resulting in nine data points per panel member. The
mean Ct values were calculated for the microbe NAs in each panel sample (Table 2). Sensitivity
and specificity calculations for each developer’s technology were scored against the CDC and
PATH reference datasets, along with their 95% confidence intervals (summarized in Table 2).
Some NA extracts were retested after initial screening to confirm whether procedural errors
accounted for unexpected results. This root cause analysis enabled the identification of misla-
beled samples from two developers, and their final RT-PCR data were corrected based on
repeat testing to account for the original labelling errors. Complete and annotated data sets for
each developer are publicly available (https://dataverse.harvard.edu/dataverse/SSB).
Sputum panel results
Developer C extracted influenza A RNA from all spiked samples with sensitivity of 100%.
Developer E extracted most influenza A RNAs, but not all RT-PCR tests were positive when
using low sample extracts (e.g. SP1), with a further three false positive replicates reported from
one extract (SP3) indicating potential cross contamination. Analyses of the Influenza A RNA
produced by Developer E’s extraction technology showed an overall sensitivity of 86% for
Influenza A RNA. Influenza A RNA from the medium (SP10) and high (SP4 and SP7) spiked
samples was produced at detectable levels by two developers (A and F), but the low-level sam-
ple (SP1) was scored as negative with these technologies. Developers B and D did not produce
Influenza A RNA in any SP extracts, even those with high-spike levels. When specificity was
considered, most developers scored 100%, with the exception of developer E scoring 93%.
Overall, developer C had the highest concordance with the predicate methods for influenza A
RNA extraction from sputum, namely Qiagen manual extraction (PATH) or the MagNaPure
(CDC).
Better overall extraction performance was observed with MTB (Table 2). Developer A cor-
rectly extracted MTB DNA from all spiked samples, whereas developers C and E managed to
produce MTB DNA from most MTB spiked samples, though not as consistently from three
replicates from the MTB low-level spiked samples (SP5 and SP7). Developers B and D were
only able to extract detectable MTB DNA from the samples with the highest-spiked levels (SP1
and SP3). Of note are the MTB DNA extracts from developer A where the Ct values generated
from testing were generally lower than the MagNaPure (CDC) and manual (PATH) data sets
Assessment of nucleic acid extraction technologies using spiked specimen types
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(Table 2), indicating that for MTB, the developer A extraction method was more efficient than
the PATH or CDC reference methods. Analyses of the extracts from developer A achieved a
sensitivity of 100%, whereas extracts from developers B, D, E and F demonstrated significantly
lower sensitivities. The extracts from most technologies scored well with regards to specificity,
with developers B, C, E and F achieving 100%, however developer A scored least well of the six
groups with their extracts generating a specificity of 86%, possibly due to cross contamination
affecting the MTB-negative sample, SP4 (Table 2). Overall, for MTB DNA extraction in spu-
tum, developer A had concordance to the reference methods amongst the six technologies, but
developer C also scored well. For the sputum panel overall, developer C demonstrated the
highest concordance to the reference methods when considering the simultaneous extraction
of both DNA and RNA targets.
Blood panel results
The extracts from developers A, B, E and F all contained detectable amounts of MS2 RNA
across the spiking range from high to low (Tables 1 and 2). However, only extracts from devel-
oper A had 100% agreement for all replicates compared to the MagNaPure (CDC) and Qiagen
(PATH) reference data. With MS2, developer A extracts gave consistently lower Ct values than
the reference data indicating the most effective purification overall. Extracts from developer F
correctly corresponded to the positive samples, but an extract from a negative sample, BL9,
gave a false positive RT-PCR result, presumably because of a cross contamination event. Devel-
oper E detected some low-spiked sample replicates (BL1 and BL6) but correctly detected all
replicates from the higher-spiked panel members (BL4, BL7, and BL10). RT-PCR on the
extracts from developer B correctly identified the majority of replicates spiked with MS2, but
surprisingly, many of the unspiked sample extracts also scored RT-PCR positive (Table 2),
resulting in poor specificity for this panel. Upon investigation it was discovered that developer
B routinely used MS2 in other development work in their laboratory, so it is possible that
reagents were contaminated with MS2 phage or MS2-related amplicons. Samples from devel-
opers C and D were non-reactive for 3/6 and 4/6, respectively, of the 6 MS2-spiked samples,
resulting in poor sensitivity. The observed specificity for developers A, C, D and E was 100%
with developer F closely following at 98%. Overall, developer A ranked highest with the MS2
challenge in whole blood with 100% sensitivity and specificity. Developer F followed with an
observed sensitivity and specificity of 100% and 98%, respectively. Developer E has slightly
lower sensitivity of 87% with a specificity of 100%.
The MagNaPure extracts gave the lowest Ct values across the panel range with S. pneumo-
niae DNA extraction from whole blood. Many of the developer’s technologies demonstrated
good performance with all spiking ranges correctly generating RT-PCR positive results
(Table 2). However, only the extracts from developer A were consistently RT-PCR positive
with all spiked replicates, resulting in a sensitivity of 100%. The replicate extracts from the
low-spiked samples (BL5 and/or BL7) as prepared by developers C, D, E, and F generated vari-
able RT-PCR results with developers E and F showing higher sensitivities at 96% and 98%,
respectively. All technologies achieved�90% specificity, with developers A, B, C, D and E
scoring 100%. Factoring in both MS2 RNA and S. pneumoniae DNA extractions from whole
blood, developer A scored best overall with similar Ct values to the reference assays used by the
CDC and PATH.
Stool panel results
The MS2 RNA extractions from stool panel were the only test panel where no developer
achieved 100% sensitivity, as not all replicate extracts derived from the low-spiked samples
Assessment of nucleic acid extraction technologies using spiked specimen types
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(ST1 and ST6) gave positive RT-PCR results (Table 2). The MagNaPure assay also performed
poorly as compared to the Qiagen method employed at PATH. The extracts from developers
A and F scored highest sensitivity with 84% and 80%, respectively. In terms of specificity,
developer B extracts again appeared to be confounded by potential MS2 contamination, but to
a lesser degree than observed with the blood panel. The extracts from other developers demon-
strated 100% specificity. Overall, developer A had the greatest concordance for extracting MS2
RNA as compared to the six technologies, with developer F being a close second. All of the pos-
itive samples had Cts�4.8 higher than the corresponding PATH data, indicating that the
extraction and/or the co-purification of confounders had significant negative effects on gener-
ating a test result.
For S. Typhimurium, developer A was the only technology whose NA extracts were
detected with 100% sensitivity. Interestingly, the sensitivities scored for extracts from the other
developers were all relatively low compared to the other microbe panels, with developer D as
the next best at 64%. All technologies scored 100% for specificity. With the stool panel, devel-
oper A had significant concordance with the data derived from the different extraction meth-
ods used at PATH and CDC than compared to any of competitors in terms of both RNA and
DNA extraction followed by developer F.
Volumetric effects on the performance of NA extraction
As with most NAATs, multiple factors may contribute to the diagnostic accuracies observed
with these six technologies. These include the amount of sample processed in a NA extraction,
the final elution volume, and the percentage of the eluate used in the amplification/detection
steps. Theoretically, processing a large amount of specimen and/or eluting captured NAs in a
smaller volume can result in a more concentrated sample, thus increasing the likelihood of
amplification target NA. The specimen input and elution volumes of each NA extraction
method varied substantially among the developers (Table 3). Inputs ranged from 80–500 μL
for sputum processing, 50–1000 μL for blood, and 70–750 μL for stool. Elution volumes ranged
from 50–105 μL and were consistent across specimen types within each technology. The per-
centage of eluate among the six technologies used in the RT-PCR step varied less, ranging
between 4.8–10%.
We examined the relationship between sample volume and elution volumes with respect to
the volume of eluate used for RT-PCR and back calculated to the amount of sample per
RT-PCR reaction. These were then compared to the overall performance ranking of each
developer using the pooled sensitivity and specificity data for each panel (Table 2). Developer
A, the overall top performer in terms of NA extraction methods being assessed, typically used
the largest amount of input material (75% - 100% of available material) with NA elution in a
final volume of 105 μL which resulted in a high percentage of sample being used. Developer F
had the greater relative amount of sample to input (100%), but only with the MTB panel.
Developers B and F also used larger sputum input and NA elution volumes, but did not
achieve the level of sensitivity seen with developer A. Developer E, who ranked third with all
matrices in terms of sensitivity, used smaller amounts of input sample (8–20% of available
material) and eluted in the smallest volume recorded (50 μL). Thus, their extraction process
was efficient in terms of extraction methodology. The developers C and D used small sample
inputs (7%- 30%) and also had poorer performance based on sensitivity, with the exception of
sputum for which developer C scored best overall using only 16% of the sputum sample.
Developer B used small sample inputs for blood and stool (10% and 25% respectively) and
eluted in the largest eluate (150 μL) noted amongst the six groups; this combination may have
contributed to the typically lower sensitivity observed across all panels (Table 2).
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Table 3. The comparative assessment of sample input amounts and NA elution volumes used by each developer.
The amounts of samples provided in each panel is shown alongside the amount of sample used for NA extraction by
each developer in addition to the elution volume. The percentage of NA eluates used for each RT-PCR reaction (5 μL
per reaction) and the percentage of sample used per RT-PCR reaction are shown with the ranking of pooled sensitivity
and specificity observed from each specimen type. NA; nucleic acid.
Group Specimen
type
NA
extracted
Sample input
(μL or mg
stool)
% of total
sample
Elution
volume (μL)
% of eluate
used for
RT-PCR
% of sample
used for
RT-PCR
PATH Sputum DNA 500 100 100 5.0 5.0
RNA 140 28 60 8.3 2.3
Blood DNA 200 20 200 2.5 0.5
RNA 140 14 60 8.3 1.2
Stool DNA 200 20 200 2.5 0.5
RNA 28 3 60 8.3 0.2
CDC Sputum DNA/
RNA
300 60 100 5.0 3.0
Blood DNA/
RNA
225.8 23 100 5.0 1.2
Stool DNA/
RNA
22.6 2 100 5.0 0.1
A Sputum DNA/
RNA
500 100 105 4.8 4.8
Blood DNA/
RNA
1000 100 105 4.8 4.8
Stool DNA/
RNA
750 75 105 4.8 3.6
B Sputum DNA/
RNA
500 100 150 3.3 3.3
Blood DNA/
RNA
100 10 150 3.3 0.3
Stool DNA/
RNA
250 25 150 3.3 0.8
C Sputum DNA/
RNA
150 30 50 10.0 3.0
Blood DNA/
RNA
50 5 50 10.0 0.5
Stool DNA/
RNA
70 7 50 10.0 0.7
D Sputum DNA/
RNA
80 16 100 5.0 0.8
Blood DNA/
RNA
80 8 100 5.0 0.4
Stool DNA/
RNA
80 8 100 5.0 0.4
E Sputum DNA/
RNA
100 20 50 10.0 2.0
Blood DNA/
RNA
100 10 50 10.0 1.0
Stool DNA/
RNA
77 8 50 10.0 0.8
F Sputum DNA/
RNA
500 100 100 5.0 5.0
Blood DNA/
RNA
250 25 100 5.0 1.3
Stool DNA/
RNA
150 15 100 5.0 0.8
https://doi.org/10.1371/journal.pone.0215753.t003
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Workflow assessment—Operator steps and processing times of candidate
extraction technologies
The ideal workflow for NAAT in RLS should be rapid and require minimal hands-on process-
ing. Each developer documented the turnaround time to process each specimen type, as well
as the number of manual operator steps required for the workflow (Fig 1). All methods
required less than one hour to complete, however processing time differences ranged from�
15 min to� 55 min, with developers B, E and F requiring the shortest turnaround times. Stool
samples required longer processing times for developers C and E (30 and 20 minutes respec-
tively) as compared to sputum or blood, due to additional steps to liquefy and clarify stool
before the NA extraction step (Fig 1). This was also evident with the work stream for developer
C who required only three operator steps for sputum and blood, yet eight for stool. Protocols
from four developers included ten operator steps for stool sample processing, reflecting that
these technologies are relatively early in workflow development or are less integrated compared
to others. The protocol with the shortest turnaround time (developer B) had the most hands-on
Fig 1. A comparison of sample processing times and manual steps to extract NAs from sputum, blood and stool specimens. Comparison or turnaround
time (min) and number of manual steps for extraction methods for developers (A-F) for each specimen type (sputum, blood, and stool). The area surrounded
by the dashed line indicates where the more optimal technologies are in terms of processing time and the number of user steps. Note, to prevent obfuscation
with clusters of multiple symbols located on a single point, in such instances each symbol is slightly diffused (where applicable) to provide clarity to the reader.
https://doi.org/10.1371/journal.pone.0215753.g001
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steps and the poorest overall performance. Developer F had a consistently short turnaround time
with� 25 minutes for all matrices. Ideally, the optimal technology will have a minimal numbers
of operator steps prior to fully automated NA extraction. Developer A, the best overall performer,
had the longest turnaround time (�55 minutes) and 6 -�10 manual steps depending on the sam-
ple type processed. Developer C had the fewest number manual steps and processing times (< 35
minutes) for sputum and blood; stool processing required 1 hour.
Ranking of developers based on key attributes. The goal of this study was to identify NA
extraction technologies that fit the requirements for integration into a test device for the
molecular detection of infectious agents. We already described the analytical performance in
terms of sensitivity and specificity of RT-PCR based detection from the NA extracts as com-
pared to reference methods using the MagNaPure (CDC) or Qiagen kits (PATH; Table 2).
While important, analytical performance is not the only metric that should be considered
when ranking the technologies. We also applied the ASSUR criteria defined in the Results sec-
tion in a series of Radar plots to visually compare each technology with each sample type
assessed for both target microbes (Fig 2). The normalized parameters in each panel were aver-
age by panel and also overall to permit ranking of each technology in comparison to simply
performance (Table 4; data file at https://dataverse.harvard.edu/dataverse/SSB).
The ASSUR rankings (Table 4) were compared to the performance ranking displayed in
Table 2. Developer F replaced A as the overall highest ranked group with changes of one or
two places for the other developers. With the sputum panel, developer C retained the highest
rank and developer F was second; developers A and E dropped one place from the original
ranking (to 4th and 3rd respectively) while B and D remained the same. The blood panel
ASSUR ranking changed for each developer as compared to performance ranking with devel-
opers F and C scoring the top rankings, respectively. The ranking of developers A and E each
dropped by two places to third and fifth whilst developer B scored fourth and D dropped to
sixth. In ranking the stool averages developer F was again ranked highest with developer B
ranked as second. This result represented the only significant increase of more than two rank-
ing places in any of the panels. Developers both dropped in the rankings to third and sixth
respectively with the reaming developers retaining the same rank.
The addition of data to further inform on the suitability of the technologies to be incorpo-
rated into a low cost NAAT resulted in slight changes to the overall ranking of technologies as
compared to performance only, though both ranking algorithms identified developers A and F
as the top two technologies developed by Akonni Biosystems and Molbio Diagnostics respec-
tively. The inclusion of turnaround times (TAT) and manual steps into the ASSUR dataset
were the underlying reasons for Molbio (F) moving ahead of Akonni Biosystems (A) A. Mol-
bio also had good performance but also a more rapid TAT (35 minutes versus 55 minutes) and
fewer user steps than the Akonni methodology and so was awarded higher ranking via the
radar plot analyses (Fig 1). Both of these developers use systems that are automated to differing
degrees with the Molbio platform hosting a cassette that processes the sample preparation
steps [33,34]. The data from other developers such as B also improved, primarily due to the
incorporation of the fastest TATs to augment their relatively poor performance data (Table 2
and Fig 1). In light of these findings, the technologies offered by Akonni and Molbio have the
best scores for consideration to enter the next stage of assessment for integration into a fully
automated stand-alone NAAT platform.
Discussion
In this study we report on an initial screen of six candidate NA extraction technologies assess-
ing their suitability for integration into a low cost NAAT cartridge with performance
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Fig 2. The comparison of each technology (developer A–F) via radar plots using ASSUR. The ASSUR criteria, as defined in the text, was applied
for each target microbe used in the three specimen panels of sputum, blood and stool. Each component for ASSUR was normalized from 0.0 to 1.0
where 1.0 represents the most optimal value within each component in the set of data points for each component. The uppermost set of three images
are examples to indicate the polar curves generated to indicate analysis via ASSUR as Good (1.0), Intermediate (0.5) and Poor (0.0) respectively. The
developers are listed as A–F and with panels for sputum (SP), Blood (BL) and sputum (SP) and plots for each target nucleic acid associated within
each panel. When the radar plot is read clockwise the letters read ASSUR; A, affordable; S, sensitivity; S, specificity; U, Number of user steps; R, rapid
turnaround time; INF, influenza A; MS2, male specific bacteriophage; MTB, M. tuberculosis; SPN, S. pneumoniae; STM, S. Typhimurium.
https://doi.org/10.1371/journal.pone.0215753.g002
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comparisons to two established NA extraction systems offered by the Roche MagNaPure
(automated) and Qiagen (manual) using contrived panels of samples that mimic common
clinical specimens. These technologies are in various phases of product development, ranging
from alpha prototypes to products that are on or close to market (e.g. Akonni and Molbio).
Therefore, poorer performance may simply reflect that the devices or methods are still being
refined. Several of the developers also noted that they normally use different protocols and
materials for extracting RNA or DNA, and thus had to make some modifications to co-extract
both DNA and RNA to meet a requirement of a potential integrated NAAT. Consequently,
some technologies may have been suboptimal under the conditions imposed for this study.
We investigated the diagnostic performance and workflow of these technologies by challeng-
ing them with three panels of contrived samples representing common specimen types used in
the NAAT-based diagnosis of multiple pathogens: 1) sputum (tuberculosis); 2) stool (diarrheal
diseases, e.g. Shigella spp.); and 3) blood (e.g. HIV, malaria, and typhoid). Target microbes
were spiked at different concentrations to assess the effectiveness of the different NA extrac-
tion methods across a range of target burdens within a complex matrix. In each panel, two
spiked microbes were selected to evaluate the efficiency of extraction from both DNA- and
RNA-based genomic targets. While the reference methods typically gave the best results, the
Akonni platform had better performance with certain target pathogens. Akonni is heavily
invested in MTB diagnostic NAATs and so their best in class performance for MTB likely
reflects their expertise in this area [35–37].
The specimen type and associated microbes were chosen to present different challenges for
NA extraction in terms of the composition of the specimen matrix [20–25,38,39], matrix asso-
ciated RT-PCR confounders [21], and the load and structural complexity of target microbes
(e.g. acid fast, gram positive/negative bacteria and RNA-base viruses). To minimize bias and
optimize extraction performance, each developer was provided with identical blinded sample
panels that were processed at their facilities, using their equipment operated by trained staff.
The NA extracts from each group were subsequently screened at a national reference labora-
tory with validated RT-PCR assays that used the same platform, reagents, users and protocols.
The six technologies were ranked in this exercise with an emphasis on extraction and detec-
tion efficacy of target NAs from complex specimen matrices. Two methods were used to score
the developers relative to each other. One was based solely on performance (i.e. sensitivity and
specificity) and the other included the turnaround time, number of manual steps and the esti-
mated cost per extraction. Based on performance, Akonni (developer A) ranked highest with
five of the six targets used in the three specimen panels. The Akonni platform is partially
Table 4. The ranking of each developers based on analyses of radial plot values. The five data points for each
ASSUR radial data point were equally weighted and the averaged data within each plot was calculated as compared to
optimal ASSUR plot values of 1.0 (Fig 2). The developers were ranked for each of the three sample panels and overall
via the average of the pooled values for both targets per sample panel and for all six targets for overall. The developers
were ranked in ascending order. The ranking of the developers based upon sensitivity and specificity only is provided
in parentheses; FLU, influenza A, MTB, M. tuberculosis; SP, sputum; MS2, male specific bacteriophage; SPN, S. pneu-
moniae; BL, blood, STM, S. Typhimurium; ST, stool.
Developer FLU MTB SP
rank
MS2 SPN BL
rank
MS2 STM ST
rank
Overall rank
A 0.65 0.67 4 (3) 0.68 0.68 3 (1) 0.61 0.64 3 (1) 2 (1)
B 0.54 0.62 5 (5) 0.61 0.71 4 (6) 0.74 0.69 2 (6) 3 = (6)
C 0.80 0.78 1 (1) 0.68 0.75 2 (4) 0.63 0.56 4 (4) 3 = (4)
D 0.44 0.49 6 (6) 0.50 0.61 6 (5) 0.59 0.60 5 (5) 6 (5)
E 0.72 0.72 3 (2) 0.65 0.66 5 (3) 0.59 0.57 6 (3) 3 = (3)
F 0.75 0.75 2 (4) 0.80 0.82 1 (2) 0.76 0.74 1 (2) 1 (2)
https://doi.org/10.1371/journal.pone.0215753.t004
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automated and utilizes their TruTip technology; a silica coated frit housed in a 1 mL micropi-
pettor tip [37]. Negative and positive air pressure is used to manipulate liquid lysed material
and buffers across the frit to sequentially capture, wash and elute NAs from a sample using an
automated pipettor [33,40]. Molbio and developer E ranked second and third, respectively, but
did not consistently detect all NA replicates in the lowest spiked samples. The Molbio platform
is the Trueprep AUTO, a battery powered instrument that hosts a cartridge-based extraction
system that utilizes Boom chemistry to capture and purify NAs [41].
Observed specificity for most methods was relatively uniform among five of the six technol-
ogies but only one developer (C) scored 100%. As with any laboratory procedure, it is possible
that contamination of specimens or extracts occurred during preparation, processing, han-
dling, or testing, as observed with MS2 in extracts from developer B. The risk of operator-
introduced contamination is lower when automated systems are used and was observed with
the both Akonni and Molbio platforms that have varying degrees of automation [33,34]. Good
laboratory practices for molecular testing laboratories were followed by all laboratories to min-
imize the potential for contamination of specimens, extracts, or PCR reactions in order to
ensure integrity of results.
The incorporation of additional metrics related to user input, TAT, and ease of use, to
assess the developers resulted in slight changes to the ranking. Molbio was ranked highest with
Akonni being second. Other developers that ranked lower on performance only scored signifi-
cantly better when these other factors were included. This is in part due to equal weighting of
the five metrics used. Some developers claimed to focus on performance with extended pro-
cessing times as compared to rapid processing times or limiting the number of user steps. It is
feasible that with protocol refinement and automation these challenges can be addressed as the
ideal test operation must have minimal or no user inputs. Costing was biased in that all devel-
opers reported that US$2 per extraction was feasible yet none are either in production or
manufacturing at a scale that can confirm accurately meeting this price.
There are several limitations to the methods used in this head-to-head study. Firstly,
because the stool and blood used to generate contrived samples were acquired from single
individuals, these may not represent the often challenging heterogeneity seen with samples
from different patients. Further, the composition of sputum and typically stool from healthy
donors is not representative of the same matrices during the course of an active infection (e.g.
presence of blood). Although the RNA and DNA-based microbes used for spiking provided a
standardized means to assess differences in extraction efficiency of the various technologies,
some targets, such as the chemically inactivated M. tuberculosis cells, may not represent the
same challenge to cell lysis as live mycobacteria. Similarly, S. pneumoniae is prone to autolysis
when cultured to late growth phase and so the cells prepared for spiking may have been par-
tially compromised during their culture, harvesting or storage. This study was focused on NA
extraction efficiency in terms of detecting specific target NAs but did not address matrix effects
associated with potential inhibitory compounds that could affect the performance of the
RT-PCR reactions [20,22,26]. It is feasible that some low ranked methods were highly efficient
at extracting NAs but an associated co-purification of confounders masked the former by
inhibiting amplification by RT-PCR. While variation in Ct values was used to semi-quantita-
tively assess NA extraction efficiencies, the wide range of sample input and elution volumes
used by the different methods makes it difficult to directly compare and normalize extraction
efficiencies.
The intent of this study was to assess different NA extraction tools to identify best in class
candidates with potential for integration into an affordable, automated test cartridge that offers
high diagnostic accuracy when combined with a suitable amplification assay. The Akonni Bio-
systems and Molbio ranked best via either scoring method. Both companies have NA
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extraction products on the market and so this exercise highlights a basic fact that products vali-
dated for release onto the market typically have better performance than a prototype that is
still in development. Several key elements necessary to meet this goal were beyond the scope of
this study, including design for manufacturing. While multiple features can be integrated into
a single test cartridge, increased design complexity typically raises manufacturing costs and/or
failure modes. One area of future investigation is to optimize for the maximum volume of elu-
ate for amplification and detection such that the eluate or an aliquot thereof is the only liquid
necessary to add to lyophilized amplification reagents. A parallel evaluation of suitable candi-
dates for NA amplification was recently completed and is presented in a companion manu-
script [42]. Ultimately, we intend to assess the most suitable methods for both NA extraction
and amplification/detection for integration and potentially enable the development of a low-
cost point of care NAAT that meets the clinical and economic challenges for use in RLS.
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